View Item 

Show simple item record

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens
dc.contributor.authorDytfeld, Dominiken_US
dc.contributor.authorRosebeck, Shaunen_US
dc.contributor.authorKandarpa, Malathien_US
dc.contributor.authorMayampurath, Anoopen_US
dc.contributor.authorMellacheruvu, Dattatreyaen_US
dc.contributor.authorAlonge, Mattina M.en_US
dc.contributor.authorNgoka, Lamberten_US
dc.contributor.authorJasielec, Jagodaen_US
dc.contributor.authorRichardson, Paul G.en_US
dc.contributor.authorVolchenboum, Samuelen_US
dc.contributor.authorNesvizhskii, Alexey I.en_US
dc.contributor.authorSreekumar, Arunen_US
dc.contributor.authorJakubowiak, Andrzej J.en_US
dc.date.accessioned2015-07-01T20:56:36Z
dc.date.available2016-08-08T16:18:39Zen
dc.date.issued2015-07en_US
dc.identifier.citationDytfeld, Dominik; Rosebeck, Shaun; Kandarpa, Malathi; Mayampurath, Anoop; Mellacheruvu, Dattatreya; Alonge, Mattina M.; Ngoka, Lambert; Jasielec, Jagoda; Richardson, Paul G.; Volchenboum, Samuel; Nesvizhskii, Alexey I.; Sreekumar, Arun; Jakubowiak, Andrzej J. (2015). "Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens." British Journal of Haematology 170(1): 66-79.en_US
dc.identifier.issn0007-1048en_US
dc.identifier.issn1365-2141en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111975
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherproteomicsen_US
dc.subject.otherbortezomiben_US
dc.subject.otherlenalidomideen_US
dc.subject.othermultiple myelomaen_US
dc.titleProteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimensen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111975/1/bjh13394-sup-0002-TableS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111975/2/bjh13394-sup-0003-TableS2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111975/3/bjh13394.pdf
dc.identifier.doi10.1111/bjh.13394en_US
dc.identifier.sourceBritish Journal of Haematologyen_US
dc.identifier.citedreferenceRichardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San‐Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. Assessment of Proteasome Inhibition for Extending Remissions I ( 2005 ). Bortezomib or high‐dose dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine 352: 2487 – 2498.en_US
dc.identifier.citedreferenceLeung‐Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J.J., Stewart, A.K., Reece, D.E., Chung, K.C. & Tiedemann, R.E. ( 2013 ) Xbp1s‐negative tumor B cells and pre‐plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell, 24, 289 – 304.en_US
dc.identifier.citedreferenceLiang, S., Xu, Z., Xu, X., Zhao, X., Huang, C. & Wei, Y. ( 2012 ) Quantitative proteomics for cancer biomarker discovery. Combinatorial Chemistry High Throughput Screening, 15, 221 – 231.en_US
dc.identifier.citedreferenceLohr, J.G., Stojanov, P., Carter, S.L., Cruz‐Gordillo, P., Lawrence, M.S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., Cibulskis, K., McKenna, A., Chapman, M.A., Straussman, R., Levy, J., Perkins, L.M., Keats, J.J., Schumacher, S.E., Rosenberg, M., Multiple Myeloma Research, C., Getz, G. & Golub, T.R. ( 2014 ) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell, 25, 91 – 101.en_US
dc.identifier.citedreferenceMartinez‐Lopez, J., Lahuerta, J.J., Pepin, F., Gonzalez, M., Barrio, S., Ayala, R., Puig, N., Montalban, M.A., Paiva, B., Weng, L., Jimenez, C., Sopena, M., Moorhead, M., Cedena, T., Rapado, I., Mateos, M.V., Rosinol, L., Oriol, A., Blanchard, M.J., Martinez, R., Blade, J., San Miguel, J., Faham, M. & Garcia‐Sanz, R. ( 2014 ) Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood, 123, 3073 – 3079.en_US
dc.identifier.citedreferenceMikhael, J.R., Dingli, D., Roy, V., Reeder, C.B., Buadi, F.K., Hayman, S.R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R.A., Lin, Y., Russell, S.J., Kumar, S., Bergsagel, P.L., Zeldenrust, S.R., Leung, N., Drake, M.T., Kapoor, P., Ansell, S.M., Witzig, T.E., Lust, J.A., Dalton, R.J., Gertz, M.A., Stewart, K., Rajkumar, S.V., Chanan‐Khan, A. & Lacy, M.Q. ( 2013 ) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk‐Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proceedings, 88, 360 – 376.en_US
dc.identifier.citedreferenceNicolas, E., Ramus, C., Berthier, S., Arlotto, M., Bouamrani, A., Lefebvre, C., Morel, F., Garin, J., Ifrah, N., Berger, F., Cahn, J.Y. & Mossuz, P. ( 2011 ) Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients. Leukemia, 25, 57 – 65.en_US
dc.identifier.citedreferenceObeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, W.J. Jr, Lee, K.P. & Boise, L.H. ( 2006 ) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907 – 4916.en_US
dc.identifier.citedreferencePaiva, B., Gutierrez, N.C., Rosinol, L., Vidriales, M.B., Montalban, M.A., Martinez‐Lopez, J., Mateos, M.V., Cibeira, M.T., Cordon, L., Oriol, A., Terol, M.J., Echeveste, M.A., de Paz, R., de Arriba, F., Palomera, L., de la Rubia, J., Diaz‐Mediavilla, J., Sureda, A., Gorosquieta, A., Alegre, A., Martin, A., Hernandez, M.T., Lahuerta, J.J., Blade, J. & San Miguel, J.F. ( 2012 ) High‐risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood, 119, 687 – 691.en_US
dc.identifier.citedreferencePatel, V.J., Thalassinos, K., Slade, S.E., Connolly, J.B., Crombie, A., Murrell, J.C. & Scrivens, J.H. ( 2009 ) A comparison of labeling and label‐free mass spectrometry‐based proteomics approaches. Journal of Proteome Research, 8, 3752 – 3759.en_US
dc.identifier.citedreferencePineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., van Rhee, F., Crowley, J., Shaughnessy, J.D. Jr & Barlogie, B. ( 2008 ) Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. British Journal of Haematology, 140, 625 – 634.en_US
dc.identifier.citedreferenceReece, D., Song, K.W., Fu, T., Roland, B., Chang, H., Horsman, D.E., Mansoor, A., Chen, C., Masih‐Khan, E., Trieu, Y., Bruyere, H., Stewart, D.A. & Bahlis, N.J. ( 2009 ) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood, 114, 522 – 525.en_US
dc.identifier.citedreferenceRichardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. ( 2002 ) Immunomodulatory drug CC‐5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063 – 3067.en_US
dc.identifier.citedreferenceRichardson, P.G., Weller, E., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L., Lunde, L.E., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C.S., Knight, R., Esseltine, D.L. & Anderson, K.C. ( 2010 ) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679 – 686.en_US
dc.identifier.citedreferenceSchewe, D.M. & Aguirre‐Ghiso, J.A. ( 2009 ) Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Research, 69, 1545 – 1552.en_US
dc.identifier.citedreferenceSchwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W. & Selbach, M. ( 2011 ) Global quantification of mammalian gene expression control. Nature, 473, 337 – 342.en_US
dc.identifier.citedreferenceShilov, I.V., Seymour, S.L., Patel, A.A., Loboda, A., Tang, W.H., Keating, S.P., Hunter, C.L., Nuwaysir, L.M. & Schaeffer, D.A. ( 2007 ) The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Molecular & Cellular Proteomics: MCP, 6, 1638 – 1655.en_US
dc.identifier.citedreferenceTaguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P.P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsypin, M., Hunsucker, S.W., Caprioli, R., Duncan, M.W., Hirsch, F.R., Bunn, P.A. Jr & Carbone, D.P. ( 2007 ) Mass spectrometry to classify non‐small‐cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross‐institutional study. Journal of the National Cancer Institute, 99, 838 – 846.en_US
dc.identifier.citedreferenceTing, L., Cowley, M.J., Hoon, S.L., Guilhaus, M., Raftery, M.J. & Cavicchioli, R. ( 2009 ) Normalization and statistical analysis of quantitative proteomics data generated by metabolic labeling. Molecular & Cellular Proteomics: MCP, 8, 2227 – 2242.en_US
dc.identifier.citedreferenceUnwin, R.D., Smith, D.L., Blinco, D., Wilson, C.L., Miller, C.J., Evans, C.A., Jaworska, E., Baldwin, S.A., Barnes, K., Pierce, A., Spooncer, E. & Whetton, A.D. ( 2006 ) Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood, 107, 4687 – 4694.en_US
dc.identifier.citedreferenceUsaite, R., Wohlschlegel, J., Venable, J.D., Park, S.K., Nielsen, J., Olsson, L. & Yates Iii, J.R. ( 2008 ) Characterization of global yeast quantitative proteome data generated from the wild‐type and glucose repression saccharomyces cerevisiae strains: the comparison of two quantitative methods. Journal of Proteome Research, 7, 266 – 275.en_US
dc.identifier.citedreferenceVellaichamy, A., Sreekumar, A., Strahler, J.R., Rajendiran, T., Yu, J., Varambally, S., Li, Y., Omenn, G.S., Chinnaiyan, A.M. & Nesvizhskii, A.I. ( 2009 ) Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS ONE, 4, e7075.en_US
dc.identifier.citedreferenceVogel, C., Abreu Rde, S., Ko, D., Le, S.Y., Shapiro, B.A., Burns, S.C., Sandhu, D., Boutz, D.R., Marcotte, E.M. & Penalva, L.O. ( 2010 ) Sequence signatures and mRNA concentration can explain two‐thirds of protein abundance variation in a human cell line. Molecular Systems Biology, 6, 400.en_US
dc.identifier.citedreferenceWang, H., Alvarez, S. & Hicks, L.M. ( 2012 ) Comprehensive comparison of iTRAQ and label‐free LC‐based quantitative proteomics approaches using two Chlamydomonas reinhardtii strains of interest for biofuels engineering. Journal of Proteome Research, 11, 487 – 501.en_US
dc.identifier.citedreferenceWard, P.S. & Thompson, C.B. ( 2012 ) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell, 21, 297 – 308.en_US
dc.identifier.citedreferenceWong, T.W., Yu, H.Y., Kong, S.K., Fung, K.P. & Kwok, T.T. ( 2000 ) The decrease of mitochondrial NADH dehydrogenease and drug induced apoptosis in doxorubicin resistant A431 cells. Life Sciences, 67, 1111 – 1118.en_US
dc.identifier.citedreferenceZhang, X.‐D., Baladandayuthapani, V., Lin, H.Y., Barlogie, B., Usmani, S.Z., Yang, L. & Orlowski, R.Z. ( 2013 ) Identification of Tight Junction Protein (TJP)‐1 As a modulator and biomarker of proteasome inhibitor sensitivity in multiple myeloma. Blood (ASH Annual Meeting Abstracts), 122, 123.en_US
dc.identifier.citedreferenceZhou, Y., Barlogie, B. & Shaughnessy, J.D. Jr ( 2009 ) The molecular characterization and clinical management of multiple myeloma in the post‐genome era. Leukemia, 23, 1941 – 1956.en_US
dc.identifier.citedreferenceZhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. ( 2011 ) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771 – 4779.en_US
dc.identifier.citedreferenceBenhar, M., Dalyot, I., Engelberg, D. & Levitzki, A. ( 2001 ) Enhanced ROS production in oncogenically transformed cells potentiates c‐Jun N‐terminal kinase and p38 mitogen‐activated protein kinase activation and sensitization to genotoxic stress. Molecular and Cellular Biology, 21, 6913 – 6926.en_US
dc.identifier.citedreferenceBolli, N., Avet‐Loiseau, H., Wedge, D.C., Van Loo, P., Alexandrov, L.B., Martincorena, I., Dawson, K.J., Iorio, F., Nik‐Zainal, S., Bignell, G.R., Hinton, J.W., Li, Y., Tubio, J.M.C., McLaren, S., O' Meara, S., Butler, A.P., Teague, J.W., Mudie, L., Anderson, E., Rashid, N., Tai, Y‐T, Shammas, M.A., Sperling, A.S., Fulciniti, M., Richardson, P.G., Parmigiani, G., Magrangeas, F., Minvielle, S., Moreau, P., Attal, M., Facon, T., Futreal, P.A., Anderson, K.C., Campbell, P.J. & Munshi, N.C. ( 2014 ). Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Communications 5, doi: 10.1038/ncomms3997.en_US
dc.identifier.citedreferenceBroyl, A., Kuiper, R., van Duin, M., van der Holt, B., el Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H.M., Goldschmidt, H., Sonneveld, P., Hg, D‐B & German, G.G. ( 2013 ) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood, 121, 624 – 627.en_US
dc.identifier.citedreferenceBurwick, N., Delrow, J.J. & Shimamura, A. ( 2013 ) Translational profiling reveals the eIF2 kinase pathway as a mediator of dexamethasone induced apoptosis in multiple myeloma. Blood (ASH Annual Meeting Abstracts), 122, 3104.en_US
dc.identifier.citedreferenceCavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P. & Baccarani, M. ( 2010 ) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem‐cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376, 2075 – 2085.en_US
dc.identifier.citedreferenceChanan‐Khan, A.A. & Giralt, S. ( 2010 ) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 2612 – 2624.en_US
dc.identifier.citedreferenceChandramouli, K, Qian, PY ( 2009 ). Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Human Genomics and Proteomics: HGP, 2009, Dec 8;2009. pii: 239204. doi: 10.4061/2009/239204en_US
dc.identifier.citedreferenceChapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.‐P., Ahmann, G.J., Adli, M., Anderson, K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsagel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R., Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Jakubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T., Lonial, S., Mahan, S., Mfuko, B., Monti, S., Perkins, L.M., Onofrio, R., Pugh, T.J., Rajkumar, S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A., Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winckler, W., Zimmerman, T., Carpten, J., Trent, J., Hahn, W.C., Garraway, L.A., Meyerson, M., Lander, E.S., Getz, G. & Golub, T.R. ( 2011 ) Initial genome sequencing and analysis of multiple myeloma. Nature, 471, 467 – 472.en_US
dc.identifier.citedreferenceCumova, J., Potacova, A., Zdrahal, Z. & Hajek, R. ( 2011 ) Proteomic analysis in multiple myeloma research. Molecular Biotechnology, 47, 83 – 93.en_US
dc.identifier.citedreferenceDe Wit, M., Keil, D., van der Ven, K., Vandamme, S., Witters, E. & De Coen, W. ( 2010 ) An integrated transcriptomic and proteomic approach characterizing estrogenic and metabolic effects of 17 alpha‐ethinylestradiol in zebrafish (Danio rerio). General and Comparative Endocrinology, 167, 190 – 201.en_US
dc.identifier.citedreferenceDeutsch, E.W., Mendoza, L., Shteynberg, D., Farrah, T., Lam, H., Tasman, N., Sun, Z., Nilsson, E., Pratt, B., Prazen, B., Eng, J.K., Martin, D.B., Nesvizhskii, A.I. & Aebersold, R. ( 2010 ) A guided tour of the Trans‐Proteomic Pipeline. Proteomics, 10, 1150 – 1159.en_US
dc.identifier.citedreferenceDimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. ( 2007 ) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 357, 2123 – 2132.en_US
dc.identifier.citedreferenceDytfeld, D., Griffith, K.A., Friedman, J., Lebovic, D., Harvey, C., Kaminski, M.S. & Jakubowiak, A.J. ( 2011 ) Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain‐ and M‐protein‐based model: extended follow‐up of a phase II trial. Leukaemia & Lymphoma, 52, 1271 – 1280.en_US
dc.identifier.citedreferenceFermin, D., Basrur, V., Yocum, A.K. & Nesvizhskii, A.I. ( 2011 ) Abacus: a computational tool for extracting and pre‐processing spectral count data for label‐free quantitative proteomic analysis. Proteomics, 11, 1340 – 1345.en_US
dc.identifier.citedreferenceGandhi, A.K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., Carmel, G., Mahmoudi, A., Jackson, P., Abbasian, M., Cathers, B.E., Schafer, P.H., Daniel, T.O., Lopez‐Girona, A., Thakurta, A. & Chopra, R. ( 2014 ) Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. British Journal of Haematology, 164, 233 – 244.en_US
dc.identifier.citedreferenceHarousseau, J.L. & Moreau, P. ( 2009 ) Autologous hematopoietic stem‐cell transplantation for multiple myeloma. The New England Journal of Medicine, 360, 2645 – 2654.en_US
dc.identifier.citedreferenceHarousseau, J.L., Attal, M. & Avet‐Loiseau, H. ( 2009 ) The role of complete response in multiple myeloma. Blood, 114, 3139 – 3146.en_US
dc.identifier.citedreferenceJakubowiak, A.J., Kendall, T., Al‐Zoubi, A., Khaled, Y., Mineishi, S., Ahmed, A., Campagnaro, E., Brozo, C., Braun, T., Talpaz, M. & Kaminski, M.S. ( 2009 ) Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 5015 – 5022.en_US
dc.identifier.citedreferenceJakubowiak, A.J., Dytfeld, D., Griffith, K.A., Lebovic, D., Vesole, D.H., Jagannath, S., Al‐Zoubi, A., Anderson, T., Nordgren, B., Detweiler‐Short, K., Stockerl‐Goldstein, K., Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M. & Vij, R. ( 2012 ) A phase 1/2 study of carfilzomib in combination with lenalidomide and low‐dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801 – 1809.en_US
dc.identifier.citedreferenceKeshamouni, V.G., Michailidis, G., Grasso, C.S., Anthwal, S., Strahler, J.R., Walker, A., Arenberg, D.A., Reddy, R.C., Akulapalli, S., Thannickal, V.J., Standiford, T.J., Andrews, P.C. & Omenn, G.S. ( 2006 ) Differential protein expression profiling by iTRAQ‐2DLC‐MS/MS of lung cancer cells undergoing epithelial‐mesenchymal transition reveals a migratory/invasive phenotype. Journal of Proteome Research, 5, 1143 – 1154.en_US
dc.identifier.citedreferenceKhan, M.L., Reeder, C.B., Kumar, S.K., Lacy, M.Q., Reece, D.E., Dispenzieri, A., Gertz, M.A., Greipp, P., Hayman, S., Zeldenhurst, S., Dingli, D., Lust, J., Russell, S., Laumann, K.M., Mikhael, J.R., Leif Bergsagel, P., Fonseca, R., Vincent Rajkumar, S. & Keith Stewart, A. ( 2012 ) A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology, 156, 326 – 333.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh13394-sup-0002-TableS1.pdf
Size:
233.7KB
Format:
PDF
View/Open
Name:
bjh13394-sup-0003-TableS2.pdf
Size:
176.8KB
Format:
PDF
View/Open
Name:
bjh13394.pdf
Size:
1.586MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.